| 2014 | Nanjing Research & Development Center Established |
| 2015-2016 | Angel Round of Financing Completed: Series-Pre-A Financing |
| 2017 | LBL-007 Entered Preclinical Research |
| 2018 | Completed Series-A Financing |
| LBL-003 Entered Preclinical Research; Completed Series-A Financing |
| 2019 | LBL-007 Clinical Application Approved |
| LBL-015 Entered Preclinical Research | |
| Signed a Licensing-out Agreement with Pneuma |
| 2020 | Completed Series-B Financing |
| LBL-003 and LBL-015 Obtained Clinical Clearance from U.S. FDA | |
| Signed Collaboration Agreement with Junshi Biosciences Co., Ltd and Xihu Biologicals |
| 2021 | Completed Series-C Financing |
| LBL-024 Obtained Clinical Clearance from U.S. FDA and China NMPA | |
| LBL-015 Obtained Clinical Clearance from China NMPA | |
| LBL-003 Obtained Clinical Clearance from China NMPA | |
| LBL-019 Obtained Clinical Clearance from U.S. FDA and China NMPA | |
| Announced Global License and Collaboration Agreement with BeiGene for Anti-LAG-3 Antibody LBL007 |
| 2022 | LBL-033 IND filed (Implied Approval for Clinical Trial by NMPA) |
| 2023 | LBL-033 Phase I Clinical Trial Initiated |
| LBL-034 First in Human Clinical Trial Application for | |
| Relapsed/Refractory Multiple Myeloma Approved by NMPA and FDA |
